Living with immunosuppression — protecting your health in Australia

What it means to be immunosuppressed

The immune system is the body’s defence network — a layered combination of physical barriers, innate responses, and adaptive immunity involving white blood cells, antibodies, and memory. When any part of this network is significantly disrupted, the ability to fight infection changes. Immunosuppression is the term used when that disruption is meaningful enough to alter clinical risk.

Immunosuppression is increasingly common in Australia. Biologics for rheumatoid arthritis, inflammatory bowel disease, psoriasis, and multiple sclerosis; chemotherapy and targeted treatments for cancer; organ and stem-cell transplantation; and longer survival with HIV have all expanded the number of Australians living with modified immune function. In general practice, managing these patients — safely, consistently, across years — is a core responsibility.

This article explains what immunosuppression means in practice, what protections are available, and how to prepare for the situations where it matters most.

A. Core clinical — the AU general-practice framework

Who counts as immunocompromised?

ATAGI — the Australian Technical Advisory Group on Immunisation uses two tiers: severely immunocompromised and less severely (moderately) immunocompromised. The distinction matters because live vaccine rules and recommended schedules differ between them.

Severely immunocompromised includes people who have had a solid-organ transplant (kidney, liver, heart, lung) or haematopoietic stem-cell transplant; those currently on chemotherapy or within six months of completion; people on anti-CD20 medicines such as rituximab or ocrelizumab within the past twelve months; those taking high-dose corticosteroids (prednisolone equivalent 20 mg or more daily for two weeks or more); those on biologics including TNF inhibitors, JAK inhibitors, and IL-targeted therapies; people on calcineurin inhibitors or antimetabolites at immunosuppressive doses; HIV with CD4 below 200; and those with primary combined or cellular immunodeficiency.

Moderately immunocompromised includes lower-dose steroids, methotrexate below 25 mg per week as monotherapy, hydroxychloroquine, sulfasalazine, HIV with CD4 200–500, chronic kidney disease stage 4–5, uncontrolled diabetes, cirrhosis, and anatomical or functional asplenia (though asplenia has its own specific bundle — see section below).

The four pillars of care

General practice addresses immunosuppression through four consistent actions:

1. Vaccinate — to the ATAGI immunocompromised schedule, not the standard schedule.
2. Screen — for hidden infections before any new immunosuppressive medicine begins.
3. Prevent — prophylactic medicines where evidence supports them.
4. Sick-day plan — clear thresholds for urgent action when infection occurs.

B. Vaccination for immunocompromised Australians

The core rule

Inactivated and recombinant vaccines are safe in immunosuppression — the vaccine cannot cause the disease it prevents. The immune response may be attenuated, but protection is still conferred. ATAGI recommends completing all indicated vaccines at least two weeks before starting immunosuppression where planned care allows.

Live attenuated vaccines are contraindicated during active cellular or combined immunosuppression because a weakened immune system cannot reliably contain the attenuated pathogen. This includes MMR (measles-mumps-rubella), varicella (chickenpox), oral typhoid Ty21a, yellow fever, intranasal influenza, BCG, and the older Zostavax shingles vaccine. After immunosuppression ends, a waiting period is required — at least three months after chemotherapy or high-dose steroids, six to twelve months after rituximab, and twenty-four months after stem-cell transplant with immunologist sign-off.

Key vaccines for immunocompromised Australians

Pneumococcal: The National Immunisation Program funds Prevenar 20 (PCV20) for immunocompromised adults; where earlier PCV13 was received, follow with PPSV23 (Pneumovax) at least eight weeks later. Government-funded.

Shingrix (recombinant zoster vaccine): Two doses two to six months apart. Government-funded for severely immunocompromised people from age 18 since November 2023. This is a recombinant vaccine — not live — and is recommended even during immunosuppression. The ZOE-70 trial (Cunningham NEJM 2016) demonstrated approximately 91% efficacy against shingles in immunocompetent adults over 70; data in immunocompromised cohorts shows meaningful protection at somewhat lower rates.

Influenza: Annual inactivated influenza vaccine, ideally before May. Government-funded. Response is reduced in patients who received rituximab recently — ideally schedule the dose before the next infusion.

COVID-19: Current ATAGI advice for severely immunocompromised patients is boosters every six months. Check the current ATAGI schedule at each visit, as recommendations evolve.

Meningococcal ACWY and MenB (Bexsero): Recommended and government-funded for asplenia, complement deficiency, and stem-cell transplant recipients. Five-yearly MenACWY booster recommended for lifelong asplenia.

Haemophilus influenzae type b (Hib): Single adult dose for asplenic patients and stem-cell transplant recipients.

C. Screening before immunosuppressive treatment

The pre-treatment screening bundle should be completed within two to six weeks of any planned biologic, chemotherapy, transplant, or long-term high-dose immunosuppression. The key components are:

Hepatitis B: HBsAg (surface antigen), anti-HBc (core antibody), anti-HBs (surface antibody). This is mandatory before anti-CD20 therapy, chemotherapy, and solid-organ transplant. A positive core antibody alone (resolved hepatitis B) on someone starting rituximab or stem-cell transplant still signals reactivation risk — preventive treatment with entecavir or tenofovir is indicated for the duration of therapy and for twelve months afterwards (APASL guidance, Lau 2020).

TB screening: IGRA blood test (QuantiFERON-Gold-Plus or T-SPOT.TB) plus chest X-ray before TNF inhibitors, JAK inhibitors, anti-CD20 therapy, and transplant. If latent TB is confirmed, treatment with isoniazid and pyridoxine for six to nine months precedes the biologic start (ASID guidelines; Pai Lancet ID 2014).

HIV and hepatitis C: Serology before any new immunosuppressant.

Varicella (chickenpox) immunity: VZV IgG. Varicella-naïve patients receive the vaccine at least four weeks before immunosuppression starts.

Dental and skin review: Oral sources of infection and baseline skin-cancer assessment — relevant because some transplant immunosuppressant regimens increase the risk of skin cancers substantially over years.

Vaccination history audit: Cross-referenced against the Australian Immunisation Register; complete all indicated vaccines with appropriate timing before treatment begins.

D. Preventive medicines — when are they needed?

Pneumocystis pneumonia (PJP) prophylaxis

Cochrane review (Stern 2014) showed trimethoprim-sulfamethoxazole (cotrimoxazole) reduces PJP incidence by approximately 85% in non-HIV immunocompromised patients when baseline risk exceeds 3.5%. It is indicated for organ transplant recipients, stem-cell transplant patients, those on prednisolone 20 mg or more for four or more weeks (particularly in combination with another immunosuppressant), acute leukaemia and certain lymphoma regimens, and HIV with CD4 below 200. The standard Australian dose is 80/400 mg (single-strength tablet) daily. Alternatives for those who cannot tolerate it include dapsone, atovaquone, or inhaled pentamidine.

Asplenia bundle (Spleen Australia)

Asplenia — from splenectomy, sickle cell disease, coeliac disease, or other causes — creates a lifelong risk of overwhelming post-splenectomy infection (OPSI) from encapsulated bacteria, with mortality up to 50%. Spleen Australia recommends registering every patient, completing the full vaccine bundle, taking daily penicillin V 250 mg twice daily (lifelong; amoxicillin or roxithromycin for penicillin allergy), carrying amoxicillin-clavulanate 875/125 mg at home as an emergency standby dose to take at fever onset before reaching emergency care, and wearing MedicAlert identification. Dog and cat bites carry special risk from Capnocytophaga canimorsus — seek immediate care and antibiotics after any animal bite.

E. Special populations

Pregnancy. Mild immune shifts occur in pregnancy, increasing susceptibility to certain infections (influenza, listeria, COVID-19). Inactivated vaccines are safe and recommended throughout pregnancy — influenza and pertussis are government-funded and strongly encouraged. Live vaccines are not given during pregnancy.

Older adults. Age-related immune decline (immunosenescence) compounds medication-related immunosuppression. Falls, malnutrition, polypharmacy, and social isolation all affect infection risk and recovery. Annual vaccination review and nutrition assessment are part of standard comprehensive geriatric assessment — see [[frailty-sarcopenia]].

Children on biologics or chemotherapy. The paediatric immunisation schedule requires modification. ATAGI and the relevant specialist team guide catch-up vaccination. School exclusion advice during outbreaks of vaccine-preventable diseases applies to immunocompromised children who may not be fully protected.

Transplant recipients. Solid-organ transplant increases skin cancer risk dramatically — squamous cell carcinoma risk is elevated sixty-five to two hundred and fifty times baseline in some series. Annual full-skin checks are standard from the first year post-transplant. Transplant-related care also includes regular cervical screening and vigilance for post-transplant lymphoproliferative disorder (B-symptoms, lymphadenopathy, weight loss).

When to escalate

Attend a hospital emergency department — do not wait — if you are immunosuppressed and experience:

• Fever of 38 °C or above — particularly if asplenic or neutropenic. This is a same-day emergency.
• New or worsening breathlessness — possible pneumonia, PJP, or pulmonary embolism.
• Expanding skin redness or warmth — rapidly progressing cellulitis.
• Severe headache with neck stiffness or light sensitivity — possible meningitis.
• Shingles spreading across the face, near the eye, or to both sides of the body.

Refer to specialist or specialist team for: pre-biologic initiation co-management; suspected reactivation of hepatitis B (rising liver enzymes); new lymphadenopathy or B-symptoms; recurrent unexplained infection (consider [[recurrent-infection-workup]]); and any suspected opportunistic infection.

What this article is and is not

This is general health information drawn from ATAGI — the Australian Immunisation Handbook, Spleen Australia, ASID guidelines, ASCIA, and current published evidence. It is not personal medical advice and does not create a doctor–patient relationship. Immunosuppression management requires individualised assessment by a GP and relevant specialist. Vaccine schedules and PBS listings change — always verify current information at the point of care.

For Australian consumer resources: Spleen Australia, Immune Deficiencies Foundation Australia, Australian Immunisation Handbook patient pages, Better Health Channel.

For urgent care: go directly to the nearest hospital emergency department.

---

Sources cited

1. ATAGI — Vaccination for people who are immunocompromised (Australian Immunisation Handbook)
2. Australian Immunisation Handbook 2024
3. Spleen Australia
4. ASCIA — Primary immunodeficiencies
5. ASID — Management of latent tuberculosis infection 2017
6. APASL — HBV reactivation prophylaxis (Lau 2020)
7. Stern A et al. — PJP prophylaxis in non-HIV immunocompromised (Cochrane 2014)
8. Cunningham AL et al. — Recombinant zoster vaccine ZOE-70 (NEJM 2016)
9. Pai M et al. — IGRA for TB detection (Lancet ID 2014)
10. National Immunisation Program Schedule 2024
11. Immune Deficiencies Foundation Australia (IDFA)